Top Page
Australian Clinical Labs Ltd
(Sydney:ACL)
Australian Clinical Labs Ltd (ACL) vs. iShares MSCI Australia ETF (EWA)
Australian Clinical Labs Ltd Business Overview & Revenue Model
Australian Clinical Labs Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 741.27M | 741.27M | 689.73M | 692.10M | 989.30M | 641.31M |
| Gross Profit | 270.86M | 270.86M | 138.45M | 566.02M | 781.71M | 521.73M |
| EBITDA | 81.36M | 81.36M | 169.65M | 184.93M | 372.75M | 196.67M |
| Net Income | 32.43M | 32.43M | 23.93M | 35.90M | 178.24M | 60.37M |
Balance Sheet | ||||||
| Total Assets | 574.84M | 574.84M | 593.06M | 578.91M | 628.04M | 474.70M |
| Cash, Cash Equivalents and Short-Term Investments | 22.12M | 22.12M | 26.84M | 20.59M | 27.51M | 36.28M |
| Total Debt | 290.38M | 290.38M | 308.90M | 316.32M | 262.38M | 294.26M |
| Total Liabilities | 402.86M | 402.86M | 415.30M | 406.24M | 395.49M | 392.79M |
| Stockholders Equity | 171.35M | 171.35M | 177.53M | 172.42M | 232.44M | 81.90M |
Cash Flow | ||||||
| Free Cash Flow | 174.39M | 174.39M | 153.09M | 136.75M | 262.83M | 144.36M |
| Operating Cash Flow | 182.80M | 182.80M | 159.59M | 143.68M | 284.09M | 153.86M |
| Investing Cash Flow | -8.89M | -8.89M | -7.25M | -12.18M | -72.04M | -6.08M |
| Financing Cash Flow | -178.74M | -178.74M | -146.14M | -137.88M | -220.91M | -147.37M |
Australian Clinical Labs Ltd Technical Analysis
Australian Clinical Labs Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$524.72M | 15.63 | 18.59% | 4.79% | 6.73% | 37.16% | |
64 Neutral | AU$10.27B | 19.43 | 6.32% | 5.15% | 9.44% | -0.37% | |
55 Neutral | AU$977.07M | 172.37 | 0.94% | 2.56% | 33.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | €635.37M | -1.21 | -67.21% | ― | -23.02% | 33.11% |
Australian Clinical Labs Ltd Corporate Events
Australian Clinical Labs Ltd has announced a change in the director’s interest in securities. Stephen Roche, a director, has acquired 70,000 ordinary shares at $2.77 per share, marking his direct interest in the company through the Steann Superannuation Fund. This transaction, conducted on-market, indicates a significant personal investment by the director, potentially reflecting confidence in the company’s future performance.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.85 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced the final notification of its buy-back program, where a total of 6,042,629 ordinary fully paid securities were bought back for a total consideration of AUD 19,101,121.57. This buy-back is part of the company’s strategic financial management, potentially impacting its market positioning by reducing the number of outstanding shares, which may enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the results of its 2025 Annual General Meeting, where several key resolutions were passed, including the re-election of directors Sarah Butler, Grant Jeffery, Stephen Roche, and Mark Haberlin, as well as the adoption of the 2025 Remuneration Report. The spill resolution was not carried. These outcomes reflect the company’s stable governance structure and commitment to maintaining its leadership team, which may reassure stakeholders about the company’s strategic direction and operational continuity.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited announced the withdrawal of Resolution 5 from its Annual General Meeting agenda following the resignation of Dr. Leanne Rowe AM. The meeting will proceed as planned on 23 October 2025. This change reflects an adjustment in the company’s governance structure, potentially impacting its strategic direction and stakeholder engagement.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited announced the resignation of Dr. Leanne Rowe AM from its Board, effective immediately, due to personal reasons. Dr. Rowe, who joined the Board during the company’s IPO in April 2021, brought significant medical and leadership expertise, contributing greatly to the Board’s skill set and supporting the senior executive team. Her departure is noted as a loss for the company, which expressed gratitude for her contributions and wished her well in future endeavors.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited (ACL) has reached a resolution with the Australian Information Commissioner regarding a civil penalty proceeding related to a cyberattack on its Medlab Pathology business. The Federal Court of Australia has approved an agreement requiring ACL to pay $5.8 million in civil penalties and contribute $400,000 towards legal costs, concluding the proceedings and potentially impacting ACL’s financial standing and stakeholder relations.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has reached an agreement with the Australian Information Commissioner to resolve a civil penalty proceeding related to a cyberattack on Medlab Pathology, which occurred shortly after ACL acquired the business. The agreement includes a proposed penalty of $5.8 million and a contribution of $400,000 towards legal costs, pending Federal Court approval. The cyberattack did not affect ACL’s systems, and the company has since integrated Medlab’s IT systems into its own robust cybersecurity framework. This resolution allows ACL to focus on its strategic goals and continue delivering high-quality pathology services.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced the details for its 2025 Annual General Meeting, including the AGM Notice of Meeting, Proxy Form, Shareholder Question Form, and an Online Guide from Link Market Services. The announcement also includes the release of the company’s 2025 Annual Report, which encompasses the Corporate Governance Statement. This release is significant for stakeholders as it provides insights into the company’s governance and operational strategies, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced its 2025 Annual General Meeting, scheduled for October 23, 2025. The announcement includes details such as the AGM notice, proxy form, shareholder question form, and an online guide from Link Market Services. This meeting and the accompanying 2025 Annual Report, which includes the Corporate Governance Statement, are significant for stakeholders as they provide insights into the company’s governance and strategic direction.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has released several documents related to its 2025 Annual General Meeting, including the AGM Notice of Meeting, Proxy Form, Shareholder Question Form, and an Online Guide from Link Market Services. The company also published its 2025 Annual Report, which includes the Corporate Governance Statement. This release indicates ACL’s commitment to transparency and adherence to corporate governance standards, potentially strengthening its position within the pathology services industry and providing stakeholders with confidence in its operational integrity.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced a dividend distribution of AUD 0.09 per share for its ordinary fully paid securities. The dividend relates to the six-month period ending on June 30, 2025, with the ex-dividend date set for September 1, 2025, and payment scheduled for September 23, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders and may positively impact its market positioning by reinforcing investor confidence.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has released its financial results for the fiscal year 2025. The announcement includes the FY25 financial statements, statutory reports, and an investor presentation. This release is significant for stakeholders as it provides insights into the company’s financial health and operational performance, potentially impacting its market positioning and future strategic decisions.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited announced it will release its financial and operating results for the year ending June 30, 2025, on August 26, 2025. The announcement includes an investor webinar hosted by CEO Melinda McGrath and CFO Matt Cordingley, which will provide stakeholders with insights into the company’s performance and strategic direction. This event is significant for stakeholders as it offers a platform for understanding ACL’s financial health and future plans, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.60 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced a change in its substantial holding status as of March 3, 2025. The company, which operates within the healthcare sector, has seen a shift in the relevant interests and associations of its voting securities, indicating a potential impact on its shareholder structure and market positioning.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.60 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Macquarie Group Limited, along with its controlled entities, has ceased to be a substantial holder in Australian Clinical Labs Limited. This change in substantial holding may impact the company’s shareholder structure and influence its market dynamics, although specific implications for stakeholders are not detailed in the release.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.60 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced that it will release its financial results for the year ending June 30, 2025, on August 26, 2025. The company’s Annual General Meeting is scheduled for October 23, 2025, with details to be shared with shareholders. This announcement outlines the procedural requirements for shareholders wishing to nominate candidates for the board, emphasizing the company’s commitment to governance and stakeholder engagement.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.60 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.